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In this issue of Immunity, Tsujimura et al. (2008) report that the release of platelet-activating factor by
basophils stimulated with immunoglobulin G1 (IgG1)-antigen immune complexes contributes substantially
to the expression of an IgG1-dependent alternative pathway of systemic anaphylaxis in mice.Not so long ago, some investigators
thought that mice might entirely lack ba-
sophils [reviewed in (Urbina et al., 1981)].
Tsujimura et al. (2008) have now helped
highlight the importance of mouse baso-
phils by providing strong evidence that
these cells can contribute substantially
to fatal systemic anaphylaxis.
The least prevalent of circulating granu-
locytes, basophils usually account for less
than 1% of blood leukocytes in normal
humans or mice (Marone et al., 2002; Galli
et al., 2005). Basophils share several strik-
ing similarities with mast cells, including
expression of the high-affinity receptor
for immunoglobulin E (IgE) (Fc3RI), the
ability to secrete—upon stimulation with
IgE and specific antigen—a similar, but
not identical, spectrum of mediators and
cytokines, and the presence of cytoplas-
mic granules that stain metachromatically
with certain basic dyes (Marone et al.,
2002; Galli et al., 2005).
However, mature mast cells are not
normally present in the blood, but instead
enter tissues as immature progenitors
that undergo the last stages of their devel-
opment in those anatomical sites where
they ultimately will reside (Marone et al.,
2002; Galli et al., 2005). In contrast, baso-
phils typically mature in hematopoietic
tissues and then, like neutrophils and
eosinophils, circulate in the blood until
they areeliminatedor recruited into tissues
(Marone et al., 2002; Galli et al., 2005).
Among the many proposed functions of
basophils in health and disease (Marone
et al., 2002; Galli et al., 2005), there has
been particular interest in the extent to
which basophils can contribute to sys-
temic anaphylaxis (Bochner and Lichten-
stein, 1991; Galli, 2005). In humans and
other mammals, systemic anaphylaxis
(or, simply, anaphylaxis) can be inducedwhen certain unfortunate subjects previ-
ously sensitized to an antigen are later
exposed to even very small amounts of
that antigen, which is rapidly followed by
the development of severe and some-
times fatal pathophysiological responses
(Bochner and Lichtenstein, 1991; Galli,
2005). Because anaphylaxis can be in-
duced by antigens derived from intrin-
sically innocuous substances, such as
components of peanuts or other foods,
anaphylaxis is arguably the most gro-
tesque example of a pathological imbal-
ance between the cost and benefit of an
acquired immune response.
Several lines of evidence suggest that
both mast cells and basophils contribute
to systemic anaphylaxis in humans
(Bochner and Lichtenstein, 1991; Marone
et al., 2002; Galli, 2005; Galli et al., 2005).
Clinical observations indicate that thema-
jor antibody isotype responsible for ana-
phylaxis in humans is IgE, document that
signs and symptoms of anaphylaxis can
be observed within seconds of intrave-
nous exposure to specific antigen, and
show that anaphylaxis can be associated
with evidence of basophil, as well as mast
cell, activation (Bochner and Lichtenstein,
1991; Marone et al., 2002; Galli, 2005;
Galli et al., 2005). Both mast cells and
basophils can rapidly secrete histamine,
lipid mediators, and other biologically
active products upon activation with IgE
and specific antigen. Further, given the
cells’ anatomic distribution, blood-borne
antigens will first encounter basophils be-
fore gaining access to tissues, where they
would then encounter mast cells. How-
ever, the role of basophils in systemic
anaphylaxis in the mouse has remained
an open question.
Why is that? First, mouse basophils
have been difficult to study. They can beImmidentified on the basis of their ultrastruc-
tural features (Dvorak et al., 1982), but
this is a problematic way to attempt to
analyze their functions in vivo. Second,
in contrast to mast cells, whose functions
can be analyzed in mice that genetically
lack mast cells but which can be en-
grafted with normal or genetically altered
mast cells (Galli et al., 2005), no mutant
mice have been reported that selectively
lack basophils. Finally, although it has
been known for many years that either
IgE or IgG1 antibodies can mediate anti-
gen-specific fatal anaphylaxis in mice
and that fatal anaphylaxis can be elicited
in mice that virtually lack mast cells (or
that lack IgE or the IgE-binding a chain
of Fc3RI) [reviewed in (Miyajima et al.,
1997; Tsujimura et al., 2008)], evidence
has been presented indicating that the
macrophage is the main source of plate-
let-activating factor (PAF) and perhaps
other mediators that are responsible for
IgG1-dependent systemic anaphylaxis in
mice [reviewed in (Finkelman, 2007)].
In this issue of Immunity, Tsujimura
et al. (2008) now report several lines of
evidence strongly implicating basophils
as an important source of PAF, and as
the cell type most responsible for a fatal
outcome, in IgG1-mediated anaphylaxis
in mice. When either normal (C57BL/6)
or genetically mast-cell-deficient C57BL/
6-KitW-sh/W-sh mice were passively sen-
sitized with Penicilin V (PenV)-specific
IgG1 monoclonal antibodies (mAbs) and
then challenged with PenV conjugated to
bovine serum albumin (PenV-BSA) intra-
venously, both types of mice developed
systemic anaphylaxis (as measured by
a drop in rectal temperature). However,
C57BL/6-KitW-sh/W-sh mast-cell-deficient
mice had a less severe drop in tempera-
ture than did control mice. These resultsunity 28, April 2008 ª2008 Elsevier Inc. 495
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tachycardia and changes in pulmonary
function, as well as the mortality, associ-
ated with a different model of IgG1-de-
pendent passive anaphylaxis were less
dramatic in WBB6F1-Kit
W/W-v mast-cell-
deficient mice than in the corresponding
wild-type mice (Miyajima et al., 1997).
Among several hematopoietic lineages
assessed by flow cytometry, basophils
displayed the highest expression of
IgG1- and FcgRII- or FcgRIII-dependent
surface capture of PenV-BSA. Moreover,
in vivo depletion of basophils (to 10%–
20% of normal numbers) in C57BL/6
mice with a mAb (Ba103) to CD200R3
greatly suppressed anaphylactic shock
induced either by anti-PenV IgG1 and
PenV or by another IgG1 antibody, anti-
2,4,6-trinitrophenol (TNP) IgG1, and
TNP-BSA, whereas basophil depletion
did not markedly influence IgE-mediated
passive anaphylaxis. Suppression of
IgG1-mediated anaphylaxis also was
observed in Ba103-treated mast-cell-
deficient mice. Hence, Tsujimura et al.
(2008) concluded that basophils play
a critical role in IgG1-, but not IgE-, medi-
ated passive systemic anaphylaxis.
Treatment with the PAF antagonist,
CV6209, prior to IgG1 and antigen chal-
lenge almost completely blocked IgG1-
mediated anaphylaxis in both wild-type
and mast-cell-deficient mice. In contrast,
inhibition of histamine and serotonin with
cyproheptadine, which substantially re-
duced the drop in temperature associated
with IgE-dependent anaphylaxis, had little
or no effect on IgG1-mediated anaphy-
laxis. The authors concluded from this
and other evidence that PAF, not hista-
mine or serotonin, was a critical mediator
of IgG1-mediated anaphylaxis, and baso-
phils were the most likely source of PAF.
To assess the role of basophils in ac-
tive systemic anaphylaxis (in which both
IgE and IgG1 antibodies are involved),
mice were immunized with PenV-OVA or
TNP-OVA and challenged intravenously
14 days later with PenV-BSA or TNP-
BSA. Strikingly, pretreatment with Ba103
to deplete basophils 1 day before antigen
challenge protected mast-cell-deficient
mice, but not wild-type mice, from death
due to active anaphylaxis. These findings
support the conclusion that both baso-
phils and mast cells played important
but distinct roles in these models of active
anaphylaxis, probably reflecting their in-496 Immunity 28, April 2008 ª2008 ElsevierFigure 1. Contributions of Mast Cells and Basophils to Systemic Anaphylaxis in Mice
In sensitized mice that have been injected with specific antigen (Ag) invtravenously, Ag can be recognized
by basophils that have bound Ag-specific IgE to surface Fc3RI, or can form immune complexes with
Ag-specific IgG1 antibodies. By diffusion through blood-vessel walls lined by vascular endothelial cells,
Ag (as well as circulating IgE and IgG1 antibodies and Ag-IgG1 immune complexes) also can gain access
tomast cells in tissues, especially at sites of enhanced vascular permeability. Ag-specific IgE and IgG1also
can beproduced locally in the tissues. Both basophils andmast cells can be activated to secretemediators
when surface Fc3RI is aggregated by the binding of Fc3RI-bound IgE to bi- ormultivalent Ag. Each cell type
also can be activated when surface FcgRIII binds immune complexes of IgG1 and specific Ag. Negative
regulation of mast cell or basophil secretion of mediators can occur if Ag bound to IgG1 (or to both IgG1
and IgE) antibodies coligates FcgRIII (or Fc3RI) and the inhibitory receptor, FcgRIIb. In IgG1-dependent
passive systemic anaphylaxis, platelet-activating factor (PAF) derived from basophils is a major mediator
of the pathophysiology.volvement in the IgG1- (basophils) versus
IgE- (mast cells) dependent components
of the response.
Using the terminology introduced by
Finkelman and colleagues (Finkelman,
2007), Tsujimura et al. (2008) proposed
that two distinct pathways can result in
systemic anaphylaxis in mice: a classical
pathway consisting of antigen, IgE,
Fc3RI, mast cells, and histamine and an
alternative pathway consisting of IgG1-
antigen immune complexes, FcgRIII,
basophils, and PAF (Figure 1).
Does this study close the book on the
roles of basophils versusmast cells versus
macrophages or other cell types in ana-
phylaxis in the mouse? Not entirely. As
always, the conclusions of this study are
based on the models used, and these re-
lied heavily on the specificity and efficacy
of Ba103 and the other antibodies that
were used to deplete specific hematopoi-
etic cell types. As noted by Tsujimura et al.
(2008), Ba103 identifies CD200R3 on both
basophils and mast cells (Obata et al.,Inc.2007). Even though treatment with
Ba103 did not substantially influence the
magnitude of IgE-mediated local cutane-
ous or systemic anaphylaxis in normal
mice (Obata et al., 2007), nor did short-
term treatment with Ba103 deplete skin
or peritoneal mast cell populations
in vivo (Obata et al., 2007), the authors
have not formally excluded the possibility
that Ba103 might influence IgG1-depen-
dent anaphylaxis in part through effects
onmast cell function. For example, the en-
hanced vascular permeability associated
with anaphylaxis might increase exposure
of tissue mast cells, which also express
FcgRIII (as well as the inhibitory receptor,
FcgRIIb), to IgG1-antigen immune com-
plexes (Figure 1). However, IgG1-depen-
dent passive systemic anaphylaxis, as
well as fatal active anaphylaxis, can be
observed in the virtual absence of mast
cells (Miyajima et al., 1997; Tsujimura
et al., 2008), and treatment with Ba103
markedly diminished the severity of
each of these models of anaphylaxis in
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2008); these facts strongly support the
conclusion that basophils can contribute
importantly to the pathology of both pas-
sive IgG1-dependent and fatal active
anaphylaxis.
Should we now dismiss the possibility
that macrophages also can contribute im-
portantly to IgG1-dependent anaphy-
laxis? Probably not. Tsujimura et al.
(2008) used mice of a single strain back-
ground (C57BL/6) to investigate models
of passive or active anaphylaxis to PenV
or TNP-BSA; in each case, mice were
challenged with antigen intravenously. It
is possible that macrophages (as well as
additional cell types that can produce
PAF or other bioactive mediators) may
contribute to the pathology observed in
other models of anaphylaxis, such as
those studied by Finkelman and col-
leagues [reviewed in (Finkelman, 2007)],
and/or in models of anaphylaxis induced
in other strains of mice.Finally, it is obvious that the conclusions
of Tsujimura et al. (2008) apply to mice
(specifically, C57BL/6 mice), and many
questions remain about the extent towhich
findings in this or other studies of mouse
modelsofanaphylaxiscanhelp toelucidate
the pathology of anaphylaxis in humans
(Bochner and Lichtenstein, 1991; Miyajima
et al., 1997; Galli, 2005; Finkelman, 2007;
Tsujimura et al., 2008). Nevertheless, the
mouse basophil is making progress: from
a cell whose existence was disputed to
center stage in the efforts to understand
the complex and redundant mechanisms
responsible for the most devastating of
acute allergic disorders, anaphylaxis.
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